Intravenous mAb GC1118 was evaluated in a multicenter, open-label, single-arm phase II trial (NCT03618667, https://clinicaltrials.gov/study/NCT03618667, accessed on 27 October 2024) in recurrent glioblastoma patients with EGFR amplification; however, despite being relatively well tolerated, it did not show benefit in PFS or OS [129]. This evidence concerns the gene EGFR and glioblastoma.